R&I – FS
A vaccine against Covid-19 is in sight, with the announcement of the first interim results in large-scale trials showing the Pfizer/BioNTech candidate is 90% effective, according to the manufacturers.
Their analysis shows a much better performance than most experts had hoped for.
The high percentage of those protected makes the findings compelling. Regulators have said they would approve a vaccine that is just 50% effective – protecting half those who get it. The company says there have been no serious side-effects.
“We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen.”
Ubudian Roy
Article URL : https://www.theguardian.com/world/2020/nov/09/covid-19-vaccine-candidate-effective-pfizer-biontech